Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border
about
Malaria in the Greater Mekong Subregion: heterogeneity and complexityArtemisinin Resistance in Plasmodium falciparum MalariaThe perils of PCR: can we accurately 'correct' antimalarial trials?Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugsAntimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR NetworkNext-generation antimicrobials: from chemical biology to first-in-class drugsDisruption of a Plasmodium falciparum Multidrug Resistance-associated Protein (PfMRP) Alters Its Fitness and Transport of Antimalarial Drugs and GlutathioneOrigin and evolution of sulfadoxine resistant Plasmodium falciparumAn open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in AsiaArtesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trialAre patent medicine vendors effective agents in malaria control? Using lot quality assurance sampling to assess quality of practice in Jigawa, NigeriaIn vitro sensitivity of Plasmodium falciparum from China-Myanmar border area to major ACT drugs and polymorphisms in potential target genesThe Ionic and hydrophobic interactions are required for the auto activation of cysteine proteases of Plasmodium falciparumImproving pharmacokinetic-pharmacodynamic modeling to investigate anti-infective chemotherapy with application to the current generation of antimalarial drugsEfficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trialChemical genetics of Plasmodium falciparumSafety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials.Divergent goals and commitments in global malaria intervention.Global Infectious Disease Surveillance at DoD Overseas Laboratories, 1999-2007Inhibitory activity of marine sponge-derived natural products against parasitic protozoa.Antimalarial activity of azadipeptide nitrilesFactors contributing to delay in parasite clearance in uncomplicated falciparum malaria in children.Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren.Evaluation of community-based systems for the surveillance of day three-positive Plasmodium falciparum cases in Western Cambodia.Different mutation patterns of Plasmodium falciparum among patients in Jimma University Hospital, Ethiopia.Synthesis, structure-activity relationship, and mode-of-action studies of antimalarial reversed chloroquine compounds.Ex vivo activity of endoperoxide antimalarials, including artemisone and arterolane, against multidrug-resistant Plasmodium falciparum isolates from Cambodia.Effects of mefloquine use on Plasmodium vivax multidrug resistanceEmerging artemisinin resistance in the border areas of Thailand.Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five-year-old Nigerian children.Intermittent preventive treatment using artemisinin-based combination therapy reduces malaria morbidity among school-aged children in Mali.Drug-Resistant Malaria: The Era of ACT.In vivo parasitological measures of artemisinin susceptibilityEfficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in children in Zaire and Uíge Provinces, angola.Multiple genetic backgrounds of the amplified Plasmodium falciparum multidrug resistance (pfmdr1) gene and selective sweep of 184F mutation in CambodiaDiscovery, mechanisms of action and combination therapy of artemisininTherapeutic efficacies of artemisinin-based combination therapies in Nigerian children with uncomplicated falciparum malaria during five years of adoption as first-line treatments.Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure.In vivo and in vitro antimalarial properties of azithromycin-chloroquine combinations that include the resistance reversal agent amlodipineChallenges and prospects for malaria elimination in the Greater Mekong Subregion.
P2860
Q21032492-580A1494-DA98-4EBB-9425-724FB006DECBQ22061852-81E2DA62-2582-47F7-AF02-1B9E5E3ECEA3Q24615919-2B848DD4-F233-4FE7-8724-112D64EADBF6Q24642214-F5CBAD6D-0E08-4116-8EE1-3F4728B9FE95Q26799713-D90E9E25-02FF-4CB5-AA40-4D5D53E6FD9AQ26799749-154B3196-7D2A-43C9-B27F-5B58D75235AEQ27861935-2B89AB88-5CC8-4022-BE47-A4DEAAE19250Q28473479-B2C1DE77-971F-4DCD-86EE-83FBC47217CEQ28474978-71C0357A-268E-4E39-B4FE-9CE19525CD71Q28478138-B8FA76D6-B932-49A6-B533-497F6838AD74Q28483689-4DC97ADB-2F00-44B4-9F05-73E6FFAD710EQ28484068-7C940708-7870-4320-979F-E1E9D78BAAACQ28484433-76B08683-CEE2-4AF8-93B7-3BA90122A5C8Q28534701-D2067E30-DDC1-459F-81FE-33EBAB330975Q28541521-B4467ACC-D658-477B-9110-71DAD3AB93C9Q29617272-038A67FF-EB6B-4142-B281-AE062294C55FQ30592761-0A47E315-9F0A-4CA4-BCA1-CB2508C8D223Q33354573-FEA616F4-2E6C-43DB-BA96-FB881F9352ABQ33578799-5BD3B596-9097-4F66-863A-16C2D5C20CFCQ33635495-56E4F289-44F8-4AAA-9D57-63266BD761CCQ33637348-F50F0C69-4842-4AEF-B8E8-933E8146D4C8Q33711891-884481F0-C8A2-4E50-9872-1792ECF24726Q33728165-D481273D-B7F1-48C9-B19F-DAD715CC36C6Q33948123-98FDC373-CF0C-4280-BC39-2FE5029F2F75Q34068703-565BDD5F-66C7-46A5-834F-9D057443C8B8Q34129945-021FBA5E-F995-4E36-ADFB-DE693430F15CQ34298916-92F49424-DCB1-46F0-AC38-4A8FDE814913Q34320936-20C2CD06-A7FA-445D-85AB-3783577859ECQ34343530-D0E1A51A-0BB7-4752-9042-9EDF9CCC5E90Q34496205-11D26DA9-269B-484B-9CDE-4DE4A64AFBD1Q34572538-83A670B3-C521-4947-BFC7-50A4532358E0Q34681141-5FF4DB2B-A4C1-43A3-B771-255E0B6EE467Q34921155-A2F4D255-3B67-479E-9EC6-096F54FA90B8Q34922694-397A7452-A2F2-4869-A1A9-68E4EF20FFA8Q34986023-0FA4EB46-11EC-4965-9CEB-C74A039D81DFQ35006418-F0362AF7-CC4E-4DC4-BCF4-EA3FC3D5715EQ35031900-2B35C10E-DDA1-4F42-AD46-C7C5E95FAEE9Q35065737-5D83F8BF-324B-41D1-B848-CEAA4D23AAD6Q35065754-1F58ECAE-6F35-4380-BD9E-95FC5CB671F7Q35163326-710F0F47-F03A-433C-BBF7-034F314E831B
P2860
Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Declining artesunate-mefloquin ...... n the Cambodia-Thailand border
@ast
Declining artesunate-mefloquin ...... n the Cambodia-Thailand border
@en
Declining artesunate-mefloquin ...... n the Cambodia-Thailand border
@en-gb
Declining artesunate-mefloquin ...... n the Cambodia-Thailand border
@nl
type
label
Declining artesunate-mefloquin ...... n the Cambodia-Thailand border
@ast
Declining artesunate-mefloquin ...... n the Cambodia-Thailand border
@en
Declining artesunate-mefloquin ...... n the Cambodia-Thailand border
@en-gb
Declining artesunate-mefloquin ...... n the Cambodia-Thailand border
@nl
prefLabel
Declining artesunate-mefloquin ...... n the Cambodia-Thailand border
@ast
Declining artesunate-mefloquin ...... n the Cambodia-Thailand border
@en
Declining artesunate-mefloquin ...... n the Cambodia-Thailand border
@en-gb
Declining artesunate-mefloquin ...... n the Cambodia-Thailand border
@nl
P2860
P921
P3181
P356
P1476
Declining artesunate-mefloquin ...... n the Cambodia-Thailand border
@en
P2093
Chansuda Wongsrichanalai
P2860
P3181
P356
10.3201/EID1405.071601
P407
P577
2008-05-01T00:00:00Z